Summary for Stiripentol

  • Trade Name: Diacomit (Biocodex SA)
  • Indications: treatment of seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam.
  • Half-life: 4.5–13 hours
  • FDA Approval Date: 08/20/2018
  • Clinically important, potentially hazardous interactions with:
    Clobazam
  • Pregnancy: Based on animal data, may cause fetal harm

Please login to view the rest of this drug profile.

Page last updated 08/20/2025

Symbol key

Incidence - Help

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness - Help

Hospitalization possible
Life threatening
Fatal

Warnings in other populations - Help

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top